Table 1.
Patient Demographics and Baseline Characteristics
| Characteristics | Patients (n = 20) |
|---|---|
| Sex, n (%) | |
| Female | 6 (30) |
| Male | 14 (70) |
| Age, y | |
| Mean (SD) | 52.6 (13.4) |
| Range | 27–75 |
| Type of psoriasis, n (%) | |
| PV | 17 (85) |
| PsA | 3 (15) |
| Duration since onset, y | |
| Median (25‒75%) | 9.5 (3.3‒13.5) |
| Range | 0.16–30 |
| PASI (0‒72) | |
| Median (before bath PUVA) (25‒75%) | 23.8 (13.6‒31.3) |
| Range | 5.6–69.3 |
| Median (after bath PUVA) (25‒75%) | 2.0 (0.9–6.3) |
| Range | 0–9.1 |
| Radiation dose, J/cm2 | |
| Mean (SD) | 58.3 (18.4) |
| Range | 34.5–106 |
| Treatment response (PASI reduction), % | |
| Median (25‒75%) | 91.2 (78.6‒94.6) |
| Range | 40.9–100 |
| Therapy place, n (%) | |
| Outpatient | 1 (5) |
| Inpatient | 19 (95) |
| Body mass index, kg/m2 | |
| Median (25‒75%) | 25.5 (23.6‒28.0) |
| Range | 18.1–41.9 |
| Smoking, n (%) | |
| Current smoker | 7 (35) |
| Previous smoker | 1 (5) |
| Never smoker | 12 (60) |
| Previous treatment, n (%) | |
| Steroid ointment | 13 (65) |
| Vit. D ointment | 8 (40) |
| UV treatment | 3 (15) |
| Immunosuppressive agents | 5 (25) |
| Etretinate | 2 (10) |
| Unknown | 2 (10) |
Abbreviations: PsA, psoriatic arthritis; PUVA, psoralen plus UVA; PV, psoriasis vulgaris; Vit, vitamin.